| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Oxyberberine targets various cellular pathways and enzymes. As an isoquinoline alkaloid, it interacts with multiple molecular targets, including topoisomerases, protein kinases, and inflammatory mediators. Its anti-inflammatory activity is mediated through inhibition of NF-κB and other inflammatory signaling pathways. Its antimicrobial activity is attributed to its ability to interfere with bacterial DNA and protein synthesis. Its anticancer effects involve induction of apoptosis and cell cycle arrest.
|
|---|---|
| ln Vitro |
In vitro, oxyberberine exhibits anti-inflammatory, antimicrobial, and anticancer activities. It reduces the production of pro-inflammatory cytokines in various cell types. Its antimicrobial activity has been demonstrated against various bacteria and fungi. Its anticancer effects include induction of apoptosis and inhibition of cell proliferation in various cancer cell lines. These activities have been characterized in various in vitro systems.
|
| ln Vivo |
In vivo, oxyberberine has demonstrated anti-inflammatory and anticancer effects in animal models. The compound has been shown to reduce inflammation in models of inflammatory diseases. Its anticancer activity has been evaluated in tumor xenograft models. Its in vivo efficacy supports its potential for therapeutic applications. Specific dosing regimens and detailed efficacy data are available in the scientific literature.
|
| Enzyme Assay |
In vitro enzyme assays for oxyberberine involve measuring its effects on enzymes involved in inflammation and cancer. Topoisomerase inhibition is assessed using purified topoisomerase enzymes and DNA substrates. Kinase inhibition is assessed using kinase activity assays. Anti-inflammatory activity can be evaluated by measuring inhibition of COX-2 or iNOS. These assays provide mechanistic insights into the compound's activities.
|
| Cell Assay |
In vitro cell-based assays for oxyberberine involve treating various cell types with the compound to assess its effects on cell viability, inflammation, and signaling. Cytokine production is measured by ELISA. Cell viability is measured using MTT or similar assays. Apoptosis is quantified by flow cytometry or caspase activity assays. Signaling pathway modulation is analyzed by Western blotting. These assays characterize the compound's pharmacological activities.
|
| Animal Protocol |
In vivo animal experiments for oxyberberine have been conducted in models of inflammation and cancer. Animals are treated with oxyberberine orally or via injection. Anti-inflammatory effects are assessed by measuring inflammatory markers and tissue histology. Anticancer effects are evaluated in tumor xenograft models. Efficacy endpoints depend on the specific model being studied.
|
| ADME/Pharmacokinetics |
Oxyberberine has a molecular weight of 337.32 and a molecular formula of C20H17NO4. It is a natural isoquinoline alkaloid derived from berberine. It is also known as 8-oxoberberine. The compound is typically soluble in organic solvents. It is typically stored under recommended conditions for natural products. Its physical and chemical properties are consistent with isoquinoline alkaloids.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for oxyberberine is not extensively reported. As a natural alkaloid, its safety profile is related to its biological activities. The compound may have cytotoxic effects at high concentrations. Comprehensive toxicological studies would be required for therapeutic development. Standard safety precautions should be taken when handling the compound.
|
| References | |
| Additional Infomation |
Oxyberberine has been reported in Arcangelisia gusanlung, Thalictrum foliolosum, and other organisms with available data.
Oxyberberine (8-oxoberberine) is a natural isoquinoline alkaloid derived from berberine. It has anti-inflammatory, antimicrobial, and anticancer properties. The compound is a metabolite of berberine. Oxyberberine has been investigated for its potential therapeutic applications. It is a research compound used in alkaloid pharmacology studies. |
| Molecular Formula |
C20H17NO5
|
|---|---|
| Molecular Weight |
351.36
|
| Exact Mass |
351.11
|
| CAS # |
549-21-3
|
| PubChem CID |
11066
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
611.5±55.0 °C at 760 mmHg
|
| Melting Point |
200-201ºC
|
| Flash Point |
323.6±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.691
|
| LogP |
3.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
607
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ZHYQCBCBTQWPLC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H17NO5/c1-23-15-4-3-12-7-14-13-9-17-16(25-10-26-17)8-11(13)5-6-21(14)20(22)18(12)19(15)24-2/h3-4,7-9H,5-6,10H2,1-2H3
|
| Chemical Name |
16,17-dimethoxy-5,7-dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(21),2,4(8),9,15(20),16,18-heptaen-14-one
|
| Synonyms |
Berlambine Ketoberberine Oxyberberine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~47.45 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (5.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8461 mL | 14.2304 mL | 28.4608 mL | |
| 5 mM | 0.5692 mL | 2.8461 mL | 5.6922 mL | |
| 10 mM | 0.2846 mL | 1.4230 mL | 2.8461 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
